Quantcast

Contract Research Organization, WCCT Global Celebrates its 28th Hepatitis C Clinical Study

March 6, 2013

WCCT Global celebrates the past 28 successful clinical studies for the Hepatitis C Virus. The contract research organization continues to push for new treatments for this terrible virus.

Costa Mesa, CA (PRWEB) March 06, 2013

WCCT Global, full service contract research organization, announces today that the organization has conducted 28 clinical studies for Hepatitis C. These studies span all phases of research including First in Human studies through late phase HCV studies. Hepatitis C effects populations all over the world. Being that Hepatitis C is responsible for 75% of all liver disease in the world, WCCT Global has made a commitment to focusing extensive energy on this therapeutic area. WCCT Global has a very large database of Hepatitis C patients that they are able to reach out to in order to quickly enroll in Hepatitis C clinical trials. WCCT Global´s VP of Business Development Talia Nikolao states, “we feel privileged to be working on treatments for the Hepatitis C virus that affects nearly 170 million people globally. We want to further progress the treatments for this terrible virus that is affecting such a large part of our global population.” WCCT Global is looking to continue to expand this early phase clinical study work with many more upcoming studies for Hepatitis C.

More about WCCT Global

WCCT Global is a multi-site, full service contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow´s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines. Would you like to find out more about WCCT Global full service offerings? To request more information about WCCT Global´s capabilities in Hepatitis C clinical studies, Click Here.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10499383.htm


Source: prweb



comments powered by Disqus